Antonio Christian Ferretti

USPTO Granted Patents = 11 (Patent Applications = 4)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 7.1

ph-index = 2

Forward Citations = 11(Granted Patents)

Company Filing History:

Signal Pharmaceuticals, Inc.

Celgene Quanticel Research, Inc.

patents

Years Active: 2017-2023

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11566004 - Process for the preparation of bromodomain inhibitor (2023-01-31),

2. 11401257 - Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses (2022-08-02),

3. 11370777 - Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same (2022-06-28),

4. 10604510 - Solid forms comprising (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[B]azepine-4-carboxami compositions thereof, and uses thereof (2020-03-31),

5. 10517873 - Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use (2019-12-31),

6. 10202364 - Forms and compositions of an ERK inhibitor (2019-02-12),

7. 10189808 - Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses (2019-01-29),

8. 10005760 - Forms and compositions of an ERK inhibitor (2018-06-26),

9. 9974786 - [object Object] (2018-05-22),

10. 9795603 - Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use (2017-10-24),

11. 9604939 - Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use (2017-03-28),

Title: **Antonio Christian Ferretti: Innovator in Bromodomain Inhibitor Research**

Introduction

Antonio Christian Ferretti is a prolific inventor based in Summit, NJ, with an impressive portfolio of 11 patents to his name. His work primarily focuses on the development of bromodomain inhibitors, showcasing his contributions to the pharmaceutical industry and his commitment to advancing medical science.

Latest Patents

Ferretti's latest patents include processes for the preparation of bromodomain inhibitors. One notable patent details the synthesis and purification of a compound referred to as Compound 1, which encompasses various crystalline, amorphous forms, solvates, and hydrates. The innovation presents scalable methods for achieving a highly pure final product. Another significant patent focuses on solid forms of a specific chemical compound, 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and outlines methods for creating and utilizing these solid forms in pharmaceutical compositions.

Career Highlights

Throughout his career, Antonio Christian Ferretti has made substantial contributions while working with notable companies such as Celgene Corporation and Signal Pharmaceuticals, Inc. His innovative research has led to advancements in compound synthesis, emphasizing the importance of chemical engineering in developing effective pharmaceutical agents.

Collaborations

Ferretti has collaborated with accomplished individuals like John Fitzgerald Traverse and Ying Li, both of whom have contributed significantly to the field. Their collective expertise has undoubtedly played a role in the successful development and patenting of Ferretti's breakthrough innovations.

Conclusion

Antonio Christian Ferretti stands out as an influential inventor in the field of pharmaceutical research. With a strong focus on bromodomain inhibitors, his patents demonstrate a commitment to improving drug development processes. As he continues to innovate, his contributions are sure to leave a lasting impact on the industry.

This text is generated by artificial intelligence and may not be accurate.